Subscribe
p1images-istockphoto-com-money-
p1images / iStockphoto.com
29 November 2018Biotechnology

NHS to save £300m in biosimilar adalimumab deals

The National Health Service (NHS) England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler